Skip to main content
OpenTrials
Completed

NCT Number: NCT04510298

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Collaborative Neuroscience Research, Garden Grove, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Is willing and able to provide written informed consent to participate in the study.
  • Has an identified reliable informant.
  • Is, in the investigator's opinion, suitable for initiating a washout from the subject's current antipsychotic regimen, if applicable, and is willing to abstain from prohibited psychotropic medications in accordance with study requirements.
  • Subjects must meet screening eligibility criteria and be in an inpatient setting prior to discontinuing antipsychotic medications.
  • Subject must be able, in the investigator's opinion, to safely discontinue prohibited psychotropic medications prior to Baseline without increased suicidality.
  • Has a primary diagnosis of schizophrenia based on the Diagnostic and Statistical Manual 5th edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Psychotic Disorders Studies.
  • Is experiencing an acute exacerbation or relapse of symptoms.
  • Is in generally good physical health, in the investigator's opinion, based on Screening medical history, physical examination, vital signs, and clinical laboratory values.
  • Has a body mass index (BMI) between 18 and 40 kg/m2, inclusive.
  • For women of reproductive potential: has a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline.
  • For women of reproductive potential and men with female partners of reproductive potential: agrees to remain abstinent from sexual intercourse or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug.

Key Exclusion Criteria:

  • Is a woman who is pregnant, breastfeeding, or less than 6 months postpartum at Screening.
  • Has any primary DSM-5 disorder other than schizophrenia, as confirmed by the MINI.
  • Fails to discontinue prohibited psychotropic medications.
  • Has, in the investigator's opinion, a significant risk of violent or destructive behavior.
  • Is currently hospitalized involuntarily or incarcerated.
  • Has a history or presence of any clinically significant medical condition, disease, or surgical history that could, in the investigator's opinion, jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug.
  • Is, in the investigator's opinion, not a suitable candidate for the study.

Treatment and study plan

SP-624

Drug

Oral Capsule

Placebo

Drug

Oral Capsule

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Number of Participants with Abnormal Clinical Laboratory Values

    Time frame: Up to 4 weeks

    chemistry, hematology, and urinalysis tests will be performed

  2. Change from Baseline in Blood Pressure (mmHg)

    Time frame: Up to 4 weeks

    Blood pressure is measured by sphygmomanometer. Change from baseline measurement will be calculated

  3. Change from Baseline in Pulse Rate (beats per minute)

    Time frame: Up to 4 weeks

    Pulse rate is measured by sphygmomanometer. Change from baseline measurement will be calculated

  4. Change from Baseline in Body Temperature (degrees celsius)

    Time frame: Up to 4 weeks

    Body temperature is measured by oral thermometer. Change from baseline measurement will be calculated

  5. Change from Baseline in Body Weight (kilograms)

    Time frame: Up to 4 weeks

    Body weight is measured by weight scale. Measurement is reported in kilograms. Change from Baseline measurement will be calculated.

  6. Change from Baseline in ECG Heart Rate (beats per minute)

    Time frame: Up to 4 weeks

    Heart rate is measured by 12-lead electrocardiogram (ECG). Change from Baseline measure will be calculated.

  7. Change from Baseline in ECG RR Interval (seconds)

    Time frame: Up to 4 weeks

    RR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.

  8. Change from Baseline in ECG PR Interval (milliseconds)

    Time frame: Up to 4 weeks

    PR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.

  9. Change from Baseline in ECG QTcF Interval (milliseconds)

    Time frame: Up to 4 weeks

    QTcF is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.

  10. Number of Participants with Abnormal Physical Examination Findings

    Time frame: Up to 4 weeks

  11. Number of Participants with treatment-emergent suicidal ideation or behavior

    Time frame: Up to 5 weeks

    Treatment-emergent suicidal ideation and/or behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments

  12. Number of Participants with treatment-emergent abnormal movements

    Time frame: Up to 4 weeks

    Treatment-emergent abnormal movements will be assessed using a battery of movement assessments

Sponsors and collaborators

Lead sponsor

Sirtsei Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Aug 12, 2020
Registry last updated
Apr 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.